Moving Early-Phase Discovery Forward with Confidence

By May 23, 2017News & Media

Custom 3D Assays and Research Services Result in Better Predictability of Drug Treatment Response

Using our proprietary 3D screening approach, Likarda researchers test different drugs with known effects in humans using the conventional pharmaceutical approach and our 3D cell cluster. In each case, the results of our 3D assays better mimicked how the drugs work in humans. Compared to conventional methods, our process allows you to better predict responses to drug treatments. And as a CRO, our turnaround time and costs are more efficient.

Likarda develops and works with 3D models in cancer, diabetes, stem cells, liver, and several other areas. We can develop cell-based assays tailored to a specific cell type of interest, whether it is human, animal, cell lines or other source of origin.

384 Vs. 200,000
Our approach to 3D cell-based testing is highly efficient, allowing us to return results with speed and accuracy. While others can create and test 384 cell clusters in a normal cell culture microplate, our proprietary micromold forms and tests 200,000 clusters in the same space.

Likarda routinely conducts assay development for projects ranging from a disease model to searching for a specific mechanism of action. Our clients, large and small, rely on us to design assay systems that answer questions to guide them to the next stage, or not.

We’re known for accurate, high-quality results across all phases of drug discovery and development, including:

  • Toxicology
  • Metabolism
  • Cell health assays
  • ADME & Pharmacodynamics
  • Assay Development
  • Histology and Immunohistochemistry
  • Preclinical animal studies
  • Mass spectrometry
  • Analytical chemistry

Other services:

Leave a Reply